Clinical Innovations is now part of Laborie Medical and is a leading global provider of clinician-preferred medical devices for labor & delivery (L&D) and neonatal intensive care unit (NICU) specialties. Offering market leading products including the Koala®Intrauterine Pressure Catheter and Kiwi® Vacuum-Assisted Delivery System. Our obstetric, gynecology and neonatal portfolio include products that support the continuum of care during antenatal, intrapartum, postpartum, neonatal and gynecological surgical procedures.
For more information about our obstetric, gynecology and neonatal portfolio please visit https://www.laborie.com/obstetrics/
Commenting Policy
We appreciate your feedback and value transparency; thank you for making this community a safe and welcoming place. While we encourage lively discussion and even debate, we have a responsibility to our public and as a regulated company to make sure that this space remains an environment that is both welcoming and mutually beneficial to all of you.
In any online venue we host, create, or participate in, we are obligated to protect members, as well as ourselves. Posts and comments that include the following will be removed and such users will be reported or in some cases banned from the site. This is necessary to maintain this resource such that it meets the standards and expectations for the majority of members.
• hate speech,
• profanity,
• obscenity or vulgarity,
• nudity in profile pictures,
• defamation to a person or people,
• name calling and/or personal attacks,
• promotional,
• privacy-violating (incl. personal identifiable information),
• law/regulation-violating,
• copyright-infringing,
• off-topic will be deleted,
• unapproved products,
• competitors’ products,
• "off-label use" comments about our products,
• comments from people seeking medical advice,
• comments containing medical advice
Please know that Laborie does reserve the right to delete any posting at its sole discretion that affects the integrity of this community.
If you have any questions about these guidelines or would like to report a violation of the above terms, please visit the “Contact Us” section of our website, www.laborie.com.
Please refer to Facebooks’ and Laborie’s privacy statement for information about how personal data is handled.
For more information about our obstetric, gynecology and neonatal portfolio please visit https://www.laborie.com/obstetrics/
Commenting Policy
We appreciate your feedback and value transparency; thank you for making this community a safe and welcoming place. While we encourage lively discussion and even debate, we have a responsibility to our public and as a regulated company to make sure that this space remains an environment that is both welcoming and mutually beneficial to all of you.
In any online venue we host, create, or participate in, we are obligated to protect members, as well as ourselves. Posts and comments that include the following will be removed and such users will be reported or in some cases banned from the site. This is necessary to maintain this resource such that it meets the standards and expectations for the majority of members.
• hate speech,
• profanity,
• obscenity or vulgarity,
• nudity in profile pictures,
• defamation to a person or people,
• name calling and/or personal attacks,
• promotional,
• privacy-violating (incl. personal identifiable information),
• law/regulation-violating,
• copyright-infringing,
• off-topic will be deleted,
• unapproved products,
• competitors’ products,
• "off-label use" comments about our products,
• comments from people seeking medical advice,
• comments containing medical advice
Please know that Laborie does reserve the right to delete any posting at its sole discretion that affects the integrity of this community.
If you have any questions about these guidelines or would like to report a violation of the above terms, please visit the “Contact Us” section of our website, www.laborie.com.
Please refer to Facebooks’ and Laborie’s privacy statement for information about how personal data is handled.
Location: United States, North Carolina
Employees: 501-1000
Phone: +1 800-522-6743
Founded date: 1967
Mentions in press and media 16
| Date | Title | Description |
| 07.08.2026 | Wellspect HealthCare Establishes Strategic Advisory Board and Appoints Paul Moraviec and Michael Frazzette | Wellspect HealthCare Establishes Strategic Advisory Board and Appoints Paul Moraviec and Michael Frazzette Fri, Aug 07, 2026 17:35 CET Report this content New Strategic Advisory Board supports Wellspect HealthCare’s next phase of growth, wi... |
| 07.11.2025 | Patricia Industries’ subsidiary Laborie to acquire the JADA System | Patricia Industries’ subsidiary Laborie to acquire the JADA System Fri, Nov 07, 2025 13:32 CET Report this content Patricia Industries’ subsidiary Laborie, a leading provider of diagnostic and therapeutic medical technology products for the... |
| 11.09.2025 | Chris Smith new CEO of Laborie | Chris Smith new CEO of Laborie Thu, Sep 11, 2025 08:15 CET Report this content Laborie’s Board of Directors has appointed Chris Smith new CEO of Laborie, effective September 22, 2025. Chris Smith succeeds Michael Frazzette, who has decided ... |
| 04.11.2024 | Vensica Medical: A New Dawn in Urology Therapeutics | Vensica Medical is making waves in the world of urology. The New York City-based company recently secured $11 million in funding. This financial boost is a lifeline for innovation. It’s a step toward transforming the treatment of overactive... |
| 04.11.2024 | Vensica Medical: Urology Therapeutics Company Raises $11 Million | Vensica Medical – a pioneering urology therapeutics company, announced the closing of an $11 million funding round. This funding was led by Israel Biotech Fund (IBF), along with key strategic partners Merz (a global player in neurotoxins) a... |
| 01.11.2024 | Bright Uro: LUTS-Focused Medical Device Company Closes $32 Million (Series A) | Bright Uro, a medical device company to transform care for lower urinary tract symptoms (LUTS) through innovations in urodynamics, announced today the second closing of its Series A funding round, which was oversubscribed by nearly 40% abov... |
| 29.07.2024 | Novocuff: Medical Device Company Closes $26 Million In Series A | Novocuff – a medical device company dedicated to improving pregnancy outcomes and reducing the risk of preterm birth – announced it has successfully closed an oversubscribed $26 million Series A funding round after raising an initial $2 mil... |
| 26.07.2024 | AXA backs Novocuff | Developer of medical devices designed to prevent preterm birth Novocuff Novocuff Founded: 2021 Headquarters: San Luis Obispo, California, United States Total Funding: $28M See full company profile "> has raised $26 million in a Seri... |
| 18.07.2024 | Novocuff's Innovative Approach to Reducing Preterm Births and Saving Lives | Novocuff, a groundbreaking medical device company headquartered in the vibrant city of Mountain View, California, recently made waves in the healthcare industry by securing an impressive $26 million in Series A funding. This significant mil... |
| 17.07.2024 | Exclusive: Novocuff nets $26M to reduce preterm births | figcaption>span]:font-sans" data-chromatic="ignore"> Medical device company Novocuff raised a $26 million Series A to decrease preterm births caused by complications like cervical shortening, CEO Amelia Degenkolb tells ... |
Show more